ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Not Only Lipids And Inflammation: Insight Into A New Cause Of Heart Attack And Other Vascular Disease
deCODE scientists
report that the genetic variant on chromosome 9p21 that the company has
linked to increased risk of heart attack is also associated with up to 70%
increase in risk of abdominal aortic aneurysm (AAA) and intracranial
aneurysm (IA). This is the first common genetic variant ever found to
associate with either condition. The paper, entitled 'The same sequence
variant on 9p21 associates with myocardial infarction, abdominal aortic
aneurysm and intracranial aneurysm,' is published today in the online
edition of Nature Genetics, at http://www.nature.com/ng.
AAA and IA are the most common aneurysms - balloon-like protrusions on
arteries in the abdomen and head, respectively - and are potentially lethal
if they are left untreated and burst. "Today's findings enhance the
importance of our 9p21 variant when it comes to risk of cardiovascular
disease, and suggest that it confers this risk by affecting how artery
walls respond to other risk factors such as atherosclerotic plaque and
inflammation," said Kari Stefansson, CEO of deCODE. "As we bring these
findings into our cardiovascular therapeutics program, we are also
incorporating them into our deCODE MI diagnostic test and our deCODEme(TM)
personal genome analysis service. With today's discovery and others we
expect to announce in the weeks and months ahead, we underscore our global
leadership in human genetics and our commitment to convert this leadership
into products and the products into profit for our shareholders."
Six months ago, deCODE reported that this SNP confers significantly
increased risk of coronary artery disease (CAD) and accounts for roughly
one- third of early-onset heart attacks. This discovery has now been
replicated in studies of ten populations. The study published today was
aimed in part at investigating how this risk is conferred. To do so, the
deCODE team, - enlisting the participation of academic researchers and
thousands of their patients from Iceland, New Zealand, the Netherlands,
Finland, the US, Belgium, Sweden, Italy, Denmark and the UK - analyzed the
association of the variant with several other cardiovascular conditions.
The results show that the 'G' allele is suggestively but not definitively
associated with conditions involving the buildup of atherosclerotic plaque,
including peripheral artery disease and large artery stroke. However those
with one copy of this version of the SNP had a more than 30% greater risk
of both AAA and IA than non- carriers. Those with two copies - that is, who
inherited the risk variant form both parents - were at more than 70%
greater risk of both AAA and IA than were non-carriers. What heart attack
and these types of aneurysm have in common is that all three can result
from an abnormal or deficient remodeling and/or repair of vessel walls.
The U.S. National Heart, Lung, and Blood Institute (NHLBI) of the
National Institutes of Health (NIH) supported the recruitment of AAA sample
sets and controls from Belgium, Canada and Pennsylvania. In addition, the
Finnish intracranial aneurysm sample collection was funded in part by NIH's
National Institute of Neurological Disorders and Stroke.
About deCODE
deCODE is a biopharmaceutical company applying its discoveries in human
genetics to the development of drugs and diagnostics for common diseases.
deCODE is a global leader in gene discovery - our population approach and
resources have enabled us to isolate key genes contributing to major public
health challenges from cardiovascular disease to cancer, genes that are
providing us with drug targets rooted in the basic biology of disease.
deCODE is also leveraging its expertise in human genetics and integrated
drug discovery and development capabilities to offer innovative products
and services in DNA-based diagnostics, bioinformatics, genotyping,
structural biology, drug discovery and clinical development. deCODE is
delivering on the promise of the new genetics.(SM) Visit us on the web at
http://www.decode.com.
Any statements contained in this presentation that relate to future
plans, events or performance are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
those described in the forward- looking statements. These risks and
uncertainties include, among others, those relating to technology and
product development, integration of acquired businesses, market acceptance,
government regulation and regulatory approval processes, intellectual
property rights and litigation, dependence on collaborative relationships,
ability to obtain financing, competitive products, industry trends and
other risks identified in deCODE's filings with the Securities and Exchange
Commission. deCODE undertakes no obligation to update or alter these
forward-looking statements as a result of new information, future events or
otherwise.
deCODE genetics Inc.
http://www.decode.com
Nu numai Lipide ºi inflamaþii: Insight într-o nouã cauzã de atac de cord ºi alte vasculare Boli - Not Only Lipids And Inflammation: Insight Into A New Cause Of Heart Attack And Other Vascular Disease - articole medicale engleza - startsanatate